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Aim: To define the independent variables that affect the life spans of patients with glioblastoma multiforme (GBM).
Materials and methods: This study was conducted in the neurosurgery clinic of Erciyes University’s Faculty of Medicine, lasting from
February 2000 to September 2006. A total of 98 patients were diagnosed with GBM after tumor resections. Patients’ demographic,
neurological, radiological, surgical, and clinical features and adjunct therapies were analyzed retrospectively.
Results: Of the 98 patients, 36 (36.7%) were female and 62 (65.4%) were male. There were 15 patients (15.3%) still alive. The median
survival time (MST) of the gross total resection and subtotal resection groups was 12 and 8 months, respectively. The group with
postoperative Karnofsky performance scores (KPS) of ≥70 included 56 patients; their survival rate was 19.6% and their MST was 14
months (confidence interval [CI] 95%, 10–18). The postoperative KPS of <70 group included 42 patients; their MST was 4 months (CI
95%, 3–6) and their survival rate was 9.5%. After the radiotherapy, of the 73 patients who underwent chemotherapy, the survival rate
was 19.2% and the MST was 14 months (CI 95%, 10–18). The group without chemotherapy had a MST of 2 months (CI 95%, 1–3) and a
survival rate of 4%. In a univariate analysis, the MST of age groups I (<45), II (45–59), and III (≥60) were 15 months (CI 95%, 7–23), 10
months (CI 95%, 7–13), and 5 months (CI 95%, 3–7), respectively. The preoperative and postoperative median tumor volume detected
was 79 (14–668) and 6 (0–64) mm3, respectively.
Conclusion: Multivariate Cox regression analyses showed that prognostic factors are young age, postoperative KPS, chemotherapy, and
postoperative tumor volume.
Key words: Glioblastoma multiforme, prognosis, postoperative tumor volume, Karnofsky performance score

1. Introduction
The prognosis of patients with glioblastoma multiforme
(GBM) is not satisfactory and it continues to be expressed
in months, despite advancements in the treatment of the
disease itself (1). GBM is the most significant and malignant
diffuse primary brain tumor. In the literature there is much
controversy about the independent variables acting on
prognosis; therefore, discrepant conclusions are presented.
Major independent variables include surgical resection (1–
4), age (3–8), patients’ preoperative Karnofsky performance
scores (KPS) (1,3–9), tumor localization (1,3,5,7,8),
postoperative radiotherapy (RT), and chemotherapy (CT)
(5,7,8). Since these variables interact with each other,
detection of the primary variables that affect survival
requires research of multivariate analyses, together with
the other variables. The present study examines the effects
on the prognosis caused by variables such as the degree of
* Correspondence: mehmetali.ekici@gmail.com

surgical resection, the localization of the lesion, the age of the
patient, preoperative and postoperative KPS, complications,
reoperations, preoperative and postoperative tumor volume,
RT, and CT. These variables have been studied prospectively
using univariate and multivariate statistical analyses.
The objective of this study is to define the independent
variables affecting the life span of patients with GBM.
2. Materials and methods
The current study presents correlations of the prognoses
with adjunct therapies for 98 patients diagnosed with
GBM, based on postcraniotomy tumor resections in the
neurosurgery clinic in the Faculty of Medicine of Erciyes
University from February 2000 to September 2006. The
demographic, neurological, radiological, surgical, and
clinical features of the cases were defined retrospectively
and were assumed to affect prognosis.
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The material obtained from the surgical resection
of each case was studied by an experienced pathologist.
Histopathological diagnoses indicated GBM according to
the World Health Organization’s (WHO) standards (10).
The data regarding the patients’ radiological and clinical
features and their treatment modalities were recorded for
safekeeping in tumor follow-up forms specially designed
for this study group.
While asymptomatic patients were requested to report
back at 3-month intervals, for symptomatic patients
clinical and radiological data were recorded in forms
specially designed for monitoring tumors. Magnetic
resonance imaging (MRI) was conducted at each control
session and the results were assessed by an experienced
radiologist to determine recurrence and regrowth.
2.1. Surgical protocol
After the patients’ positions were secured by Mayfield
Nail headgear (Brain LAB Surgical Products, Cincinnati,
OH, USA) under anesthesia, the patients’ positions
were matched with neuronavigation. For the correction
of surgical deviations due to brain shift, intraoperative
ultrasound images were synchronized with navigation
images and the navigation systems were fused; this process
was continued in real time until the end of each resection as
the need arose. Intraoperative ultrasonography recordings
were separated, as required, in terms of postresection
residual tumors, and the transition to hemostasis was
realized when the resection was deemed satisfactory.
2.2. Imaging protocol
Tumor localizations and their proximity to vital areas in
the brain were quantified according to the grading system
proposed by Sawaya et al. (11) (Table 1). Preoperative and
postoperative routine computerized tomography and MRI
recordings were obtained with and without a contrast
medium, and tumor localization features were determined
by a neuroradiologist. Computerized tomography within
the first 4 h postoperatively was obtained from each
patient to diagnose any asymptomatic complications
that might be related to surgery. The extent of surgical
resection was determined by the neuroradiologist through
T1 MRI images with contrast, which were obtained during
the first 72 h postoperatively (≥95%, gross total resection;

<95%, subtotal resection). All of the patients were checked
postoperatively within the first 72 h.
2.3. Radiotherapy protocol
Of the 98 total patients, 82 patients (83.7%) received RT. The
remaining 16 patients were unable to receive RT for social
(8 patients) or medical (8 patients) reasons. An effective
irradiation area was drawn on the mask in the simulator
for each patient. The first stage of the radiotherapy, which
was performed by applying 6,000,000 electron volts (MV)
with a LINAC teletherapy device (Varian 2300c, USA)
device, targeted the area involving pathological contrast
consistent with the tumor, the area around with edema,
and 2–3 cm of brain tissue beyond this area. A dosage of
40–50 Gy was applied. In the second stage of the therapy,
however, the targeted area was narrowed further, and the
dosage was increased to 60 Gy. The dosage was limited to 60
Gy in 30 fractions for 6 weeks, which reached the tolerance
level of the central nervous system. In both therapeutic
stages, the parallel opposed field technique was used. As
a prophylactic against cerebral edema, throughout the
radiotherapy, each of the patients received 8–16 mg/day
dexamethasone, which was tapered and discontinued
within 2 weeks after the completion of the therapy.
2.4. Chemotherapy protocol
Following the pathological diagnosis, the first dose of 100
mg/m2 intravenous fotemustine was administered to 73
patients, together with the first dose of radiotherapy. The
same dose was repeated at 3-week intervals to complete 3
cycles (whereas the remaining 25 patients were unable to
receive it for economic [11 patients], social [8 patients],
and medical [6 patients] reasons). The performance
scores (hematological, renal, and hepatic functions) of the
patients accepted for CT were monitored closely at regular
intervals, and care was taken to keep the scores within
normal ranges. When abnormal values were detected,
the CT protocol was interrupted until the values were
normalized.
2.5. Statistical method
The patients’ cumulative life spans, following the dates they
were accepted for surgical operations, were determined
using the Kaplan–Meier method. Survival time curves for
various subgroups were compared by the log-rank test.

Table 1. Grading of malign astrocytomas according to functional localization (11).
Grade

Localization

I: Nonvital area

Frontal or temporal pole, parietooccipital lobe, cerebellar hemisphere.

II: Near vital area

Near motor or sensory cortex, calcarine fissure, speech center, internal capsule, dentate nucleus, and brainstem.

III: Vital area

Motor or sensory cortex, visual and speech center, internal capsule, basal ganglia, thalamus, hypothalamus,
dentate nucleus, and brainstem.
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The effects of multiple variables on patients’ survival times
were analyzed with the Cox regression method. Shapiro–
Wilk tests were used to evaluate the presences of normal
data distribution. If the data distributions were normal,
then the parametric test was used. If the data distributions
were abnormal, then a nonparametric test was used. The
values were given as medians (minimum–maximum)
for the nonparametric test results. Crude and processed
data in the study were quantified within a confidence
interval of 95%. A univariate Kaplan–Meier life analysis
and univariate and multivariate Cox regression analyses
were used to determine whether the values affecting
patient survival times were significant. Values of P <
0.05, P < 0.01, and P < 0.001 were considered statistically
significant; values of P > 0.05 were considered statistically
insignificant. For statistical analyses, SPSS 10.0 (SPSS, Inc.,
Chicago, IL, USA) was used.
3. Results
3.1. Demographic features of the patients
Of the 98 patients, 59 underwent gross total resection and
39 underwent subtotal resection. The cases comprised 36
(36.7%) female and 62 (63.3%) male patients. Their ages
ranged from 18 to 75 years, with a median of 51 years.
The male patients’ survival rate was 11.3% (n = 7), with
a median survival time (MST) of 10 months, whereas
22.2% (n = 8) of the female patients survived, with a MST
of 9 months (Table 2). In univariate and multivariate Cox
regression analysis, the sex of the patients was not detected
as a statistically significant prognostic factor (P > 0.05;
Tables 3 and 4).
3.2. Patient age
The ages of the patients ranged from 18 to 75 years, with
a median of 51 years. The patients were divided into 3
groups, according to their ages: group I included patients
younger than 45 years, group II included patients of
45–59 years old, and group III included patients above
60 years old. In a univariate analysis, the MST for the
35 patients in group I was 15 months (CI 95%, 7–23).
For the 34 patients in group II, the MST was 10 months
(CI 95%, 7–13). For the 29 patients of group III, the
MST was 5 months (CI 95%, 3–7). The findings for
groups I and II were statistically significant (P < 0.01),
and these groups had longer survival times than group
III. Group II, in particular, had a statistically significant
and longer survival time than group III (P < 0.05; Table
2). In a univariate Cox regression analysis, group I’s age
was detected as a positive prognostic factor (P < 0.001),
whereas group II’s age and group III’s age had negative
effects on prognosis (P < 0.001 and P < 0.01, respectively;
Table 3). In multivariate Cox regression analysis, there
were statistically significant differences between groups I
and III (P < 0.01 and P = 0.001, respectively), but there

was no statistically significant difference for group II (P >
0.05). For the patients in age group III, the mortality risk
was detected as 3.25 times greater (Table 4).
3.3. Functional localization of tumor
The tumors’ localizations were grouped according to the
method of Sawaya et al. (11) (Table 1). The MST of grades
I, II, and III were 18 (CI 95%, 6–30), 11 (CI 95%, 7–16),
and 8 (CI 95%, 6–11) months, and their survival rates were
13.3% (2 patients alive), 16.0% (4 patients alive), and 15.5%
(9 patients alive), respectively. No statistically significant
difference was detected in the tumor localizations’ effect
on survival times (P > 0.05; Table 2). In univariate and
multivariate Cox regression analyses, there was no
statistical significance related to the localization groups (P
> 0.05; Tables 3 and 4).
3.4. Preoperative KPS
The group with preoperative KPS of ≥70 included 69
patients whose survival rate was 15.9% (11 patients alive),
with a MST of 12 months (CI 95%, 9–15). The preoperative
KPS of <70 group included 29 patients, whose survival
rate was 13.8% (4 patients alive) with an MST of 5 months
(CI 95%, 3–7). The difference between the groups was
statistically significant, according to the MSTs (P < 0.001;
Table 2). In univariate Cox regression analysis, there was
a statistically significant difference between the groups’
preoperative KPSs (P = 0.001; Table 3). In multivariate Cox
regression analysis, preoperative KPS was not a statistically
significant prognostic factor (P > 0.05; Table 4).
3.5. Extent of resection
Of the 59 patients with gross total resection, 12 (20.3%)
were alive throughout the follow-up. The MST of the
patients in this group was 12 months (CI 95%, 9–15). In
the subtotal resection group, 3 (7.7%) of the 39 patients in
this group were alive, and the patients’ MST was 8 months
(CI 95%, 5–11). No statistically significant difference was
detected in the effect of tumor resection groups on survival
times (P > 0.05; Table 2). In univariate and multivariate
Cox regression analyses, resection degree was not a
prognostic factor, and there was no statistical significance
(P > 0.05; Tables 3 and 4).
3.6. Postoperative KPS
The postoperative KPS of ≥70 group included 56 patients;
their survival rate was 19.6% (11 patients alive) and their
MST was 14 months (CI 95%, 10–18). The postoperative
KPS of <70 group included 42 patients; their MST was 4
months (CI 95%, 3–6) and their survival rate was 9.5%
(4 patients alive). There were statistically significant
differences in the MSTs of the 2 groups (P < 0.001; Table
2). Univariate and multivariate Cox regression analyses
showed a statistically significant difference between
the postoperative KPS groups (P < 0.001 and P < 0.05,
respectively), which affected prognosis (Tables 3 and 4).

797

EKİCİ et al. / Turk J Med Sci
Table 2. Demographic, characteristics and statistical analyses of the patients with malign astrocytoma.
Variable

Description

%

n = 98

Survival rate

Median survival
time (CI 95%)

P

Age group I

<45

35.7

35

25.7

15 (7–23)

<0.01*

Age group II

45–59

34.7

34

14.7

10 (7–13)

<0.05**

Age group III

>60

29.6

29

3.4

5 (3–7)

Male

63.3

62

11.3

10(8–12)

Female

36.7

36

22.7

9(2–16)

Nonvital

15.3

15

13.3

18 (6–30)

Near vital

25.5

25

16

11 (7–16)

Vital area

59.2

58

15.5

8 (6–11)

<70

29.6

29

13.8

5 (3–7)

≥70

70.4

69

15.9

12 (9–15)

<0.001∂∂

Gross total resection

>95%

60.2

59

20.3

12 (9–15)

>0.05ϱ

Subtotal resection

<95%

39.8

39

7.7

8 (5–11)

<70

42.9

42

9.5

4 (3–6)

≥70

57.1

56

19.6

14 (10–18)

Yes

22.4

22

4.5

4 (1–7)

No

77.6

76

18.5

11 (8–14)

<0.01¢

Yes

25.5

25

20

20 (18–22)

<0.01#

No

74.5

73

13.7

8 (6–10)

With

83.7

82

17.1

11 (8–14)

Without

16.3

16

6.3

1

With

74.5

73

19.2

14 (10–18)

Without

25.5

25

4

2 (1–3)

Yes

83.67

82

17.1

11 (8–14)

No

16.33

16

6.3

8 (4–12)

Median age (range), years

51 (18–75)

15.3

10 (8–12)

Preoperative median tumor volume

79 (14–668 ) mm

Sex

Localization

Preoperative KPS

Postoperative KPS
Postoperative
complications
Reoperation
Radiotherapy
Chemotherapy
Neuronavigation

Postoperative median tumor volume

>0.05ϱ

>0.05ϱ

<0.001ǭ

<0.001Ʀ
<0.001ƈ

> 0.05ϱ

3

6

( 0–64 ) mm3

* : P < 0.01, age group I versus II and III.
**: P < 0.05, age group II versus III.
: P < 0.001, preoperative Karnofsky score of ≥70 versus <70.

∂∂

: P > 0.05 in the gross total resection versus subtotal resection, localization, sex, and operation with and without neuronavigation groups.

ϱ

: P < 0.001, postoperative Karnofsky score of ≥70 versus <70.

ǭ

: P < 0.01, postoperative complication ‘Yes’ versus ‘No’.

¢

: P < 0.01, reoperation ‘Yes’ versus ‘No’.

#

Ʀ

: P < 0.001, radiotherapy group versus group not given radiotherapy.
: P < 0.001, chemotherapy group versus group not given chemotherapy.

Ƈ
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Table 3. Univariate Cox regression analysis.
Variable

B coefficient

Standard error

OR

OR (95% CI)

P

Sex

−0.016

0.24

0.98

0.62–1.57

>0.05∆

Preoperative Karnofsky score

−0.82

0.25

0.44

0.27–0.72

0.001Ƈ

Postoperative Karnofsky score

1.13

0.23

3.11

1.97–4.90

<0.001ǭ

Reoperation

−0.76

0.26

0.47

0.28–0.79

<0.01ϱ

Radiotherapy

−1.73

0.31

0.18

0.097–0.33

<0.001Ʀ

Chemotherapy

−1.83

0.27

0.16

0.093–0.27

<0.001¢

Complication

−0.68

0.26

1.98

1.19–3.29

<0.01Ώ

Age group I

-

<0.001&

Age group II

−1.32

0.29

0.27

0.15–0.46

<0.001&

Age group III

−0.84

0.28

0.43

0.25–0.74

<0.01 &

Localization I

-

>0.05∆

Localization II

−0.56

0.33

0.57

0.30–1.08

>0.05∆

Localization III

−0.16

0.26

0.85

0.51–1.43

>0.05∆

Resection

−0.34

0.23

0.71

0.46–1.11

>0.05∆

Preoperative tumor volume

0.000

0.001

1.001

0.99–1.001

>0.05∆

Postoperative tumor volume

0.017

0.008

1.02

1.00–1.034

<0.05*

: P = 0.001, preoperative Karnofsky score of <70, which has positive survival advantages.
: P < 0.001, postoperative Karnofsky score of ≥70, which has positive survival advantages.
ϱ
: P < 0.01, patient group without reoperation has negative survival advantages in the groups with and without reoperation.
Ʀ
: P < 0.001, patient group without radiotherapy has negative survival advantages in the radiotherapy group.
¢
: P < 0.001, patient group without chemotherapy has negative survival advantages in the groups with and without chemotherapy.
Ώ
: P < 0.01, in the group developing complications, which has negative survival advantages.
&
: P < 0.001 and P < 0.01, older age groups have negative survival advantages in the age groups.
*: P < 0.01, in the postoperative tumor volume.
∆
: P > 0.05, sex, localization, resection groups, and preoperative tumor volume.
Ƈ

Ǭ

3.7. Postoperative complications
The group of patients for whom no complications
developed (n = 76) had a survival rate of 18.5% throughout
the follow-up, unlike the 4.5% rate for the group of 22
patients with complications. MST was 11 months (CI 95%,
8–14) in the group without complications, while it was 4
months (CI 95%, 1–7) in the group with complications and
the difference was statistically meaningful (P < 0.01; Table
2). In univariate Cox regression analysis, complications
were detected as a statistically significant prognostic factor
(P < 0.01; Table 3); however, this relation was not detected
in the multivariate analysis (P > 0.05; Table 4).
3.8. Reoperation
There were 25 patients who were reoperated on, and their
MST was 20 months (CI 95%, 18–22). The MST of the
patients who had no reoperations was 8 months (CI 95%,
6–10). There were statistically significant differences in

the MSTs of the 2 groups (P < 0.01; Table 2). In univariate
Cox regression analysis, reoperation was detected as a
statistically significant prognostic factor (P < 0.01; Table
3), but this relation was not detected in the multivariate
analysis (P > 0.05; Table 4).
3.9. Preoperative and postoperative tumor volume
A Shapiro–Wilk test was used to calculate preoperative and
postoperative median tumor volumes as a nonparametric
test. The preoperative median tumor volume was detected
as 79 (14–668) mm3, and the postoperative median tumor
volume was 6 (0–64) mm3 (Table 2). In univariate Cox
regression analysis, preoperative tumor volume was
detected as a statistically significant prognostic factor (P
< 0.05). In univariate and multivariate Cox regression
analyses, postoperative tumor volume was detected as a
statistically significant prognostic factor (P < 0.05), but
not preoperative tumor volume (P > 0.05; Tables 3 and 4).
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Table 4. Multiple Cox regression analysis.
Variable

B coefficient

Standard error

OR

OR (95% CI)

P

Sex

0.39

0.28

1.48

0.86–2.53

>0.05

Preoperative Karnofsky score

−0.52

0.32

0.59

0.32–1.11

>0.05

Postoperative Karnofsky score

−0.73

0.37

0.48

0.23–0.99

<0.05Ҝ

Reoperation

−0.44

0.31

0.64

0.35–1.17

>0.05

Radiotherapy

0.76

0.49

2.13

0.82–5.55

>0.05

Chemotherapy

1.45

0.44

4.25

1.78–10.13

0.001Ώ

Complication

0.28

0.33

1.32

0.69–2.51

>0.05

-

Age group I

<0.01*

Age group II

0.39

0.3

1.48

0.82–2.66

>0.05

Age group III

−1.18

0.34

3.25

1.66–6.38

0.001**

Localization I

-

>0.05

Localization II

−0.04

0.38

0.96

0.45–2.03

>0.05

Localization III

−0.61

0.4

0.54

0.25–1.19

>0.05

Resection

0.09

0.31

1.1

0.60–2.01

>0.05

Preoperative tumor volume

0.001

0.001

1.001

0.99–1.003

>0.05

Postoperative tumor volume

0.025

0.012

1.025

1.00–1.05

<0.05Ѷ

: P < 0.05, the group that had a postoperative Karnofsky score of <70 had negative survival advantages.
: P = 0.001, the patient group treated with chemotherapy had a positive life expectancy.
*: P < 0.01, the youngest age group had a positive life expectancy.
**: P = 0.001, the oldest age group had a negative life expectancy.
Ѷ
: P < 0.05, postoperative tumor volume was a prognostic factor.
P > 0.05: there were no statistically significant correlation with life expectancy.

Ҝ

Ώ

3.10. Radiotherapy/chemotherapy and survival times
Table 2 shows the patient groups with and without RT and
CT, their survival rates, and their MSTs. The MST of the
patients treated with RT was 11 months (CI 95%, 8–14),
and 17.1% of these patients were alive throughout the
follow-up. When the MST of this group was compared to
the MST of the group without RT, a statistically significant
difference was found (P < 0.01). Of the 73 patients who
underwent CT, 14 (19.2%) were alive after the treatment
with a MST of 14 months (CI 95%, 10–18). The group
without CT had a mean survival time of 2 months (CI
95%, 1–3). The differences among the median survival
times of the groups were statistically significant (P <
0.001). In univariate Cox regression analysis, RT and CT
were detected as statistically significant prognostic factors
(P < 0.001). The univariate Cox analysis found a negative
correlation between the survival rate and the treatment
group without RT and CT (Table 3). CT was a statistically
significant prognostic factor (P = 0.001; odds ratio =

800

4.25), but RT had no statistically significant relation in the
multivariate Cox regression analysis (Table 4).
4. Discussion
This study analyzed the possible prognostic factors’ effects
on prognosis. These factors included extent of resection,
age, preoperative and postoperative KPS, functional
localization, pathological diagnosis, RT, CT, reoperation,
preoperative and postoperative tumor volume, and
postoperative complications, which are all among the
independent variables acting on survival times.
4.1. The extent of resection and functional localizations
The optimal extent of resection in a patient depends on
the size and localization of the tumor, the patient’s general
and neurological condition, and the surgeon’s experience.
Sawaya et al. (11) propounded that the most important
variable for determining the neurological deficit risks
following a craniotomy is the functional localization
of the tumor. When assessing the relationship between
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surgical intervention and survival, the appropriate
method is consideration of tumor localization and the
extent of resection, which may vary depending on tumor
localization (3,5,11).
Contrary to the accepted view, this study has revealed,
through univariate and multivariate analyses, that
resection degree is not a crucial independent factor that
determines survival.
The amount of residual tumor, as seen in postoperative
MRI, was computed numerically. Numerical studies on
tumor size in patients with recurrent malign astrocytoma
(MA) report that as the postoperative size of the tumor
reduces, the survival time is prolonged significantly
(12). In addition, other studies suggested that as the
size of the resection grows, the survival time becomes
correspondingly prolonged (1–3,5). Other studies reported
that the extent of resection had no effect on survival (7,13).
Some studies on general prognostic factors have reported
that resection size has a favorable effect on survival time
(2,3,5,14). Aggressive surgical resection has less to do with
prolonging patients’ lifespans (15).
Lamborn et al. (4) divided patients into 4 risk groups,
and they found that the lowest risk group contained
patients younger than 40 years old with tumors localized
in the frontal region. The authors stressed, in light of these
observations, that localization should be considered as a
prognostic factor in future studies.
Li et al. (1), in their study of 116 patients, reported
that frontal lobe involvement is a statistically significant
marker of the delayed progression of postoperative disease.
Furthermore, they concluded that the involvement of a
vital area or deep structure is linked with poor prognosis.
The favorable effect of the degree of surgical resection is
statistically significant in univariate analyses, unlike the
multivariate analyses, in which no such effect has been
verified.
The desire to preserve neurological functions has
engendered a tendency to remove the tumors proximal
to the vital areas of the brain through biopsy or partial
resection, whereas those in nonvital areas are usually
removed through more aggressive resection (3).
In this study, the effect of the tumor’s functional
localization on survival time was not found to be
statistically significant in univariate and multivariate
analyses. Although some studies (1,3,4,7,8,11) reported
that localization is a crucial and effective factor in
prognosis, others (6,14) reported the absence of a
relationship between localization and prognosis.
Although tumors with localizations in functional
areas are associated with shorter survival times (1,3,8),
this study found that functional localization has no effect
on survival times in univariate and multivariate analyses.
This discrepancy is ascribed to the boundaries of surgical

resection and vital areas being determined through
navigation. For the obtainment of optimal tumor resection,
it is necessary to use navigation technology, together with
the surgical microscope and ultrasonography compatible
with that technology.
4.2. Patient age
This study detected a strong association between younger
ages and survival. The patients in age groups I (below 45
years) and II (45–49 years) had a statistically significant
advantage over the patients in group III (60 years and
above).
There is significant evidence of the relationship
between patients’ young ages and longer survival times in
adult patients with MA (3–8). Consequently, patient age
is an independent variable that determines the choice of
surgical method and hence the survival time.
As age increases, so does mortality risk. Aggressive
therapies administered to old patients are less effective,
whereas they prolong survival times in young patients
(5,15).
The incidence of MA in old patients is important,
and it may rise with advancing age (16). Uzuka et al.
(17) suggested that maximal safe resection is an optimal
treatment followed by radiochemotherapy using
temozolomide (TMZ), regardless of age and KPS, for
patients with GBM.
In summary, there is strong evidence of the relationship
between adult patients’ young ages and longer survival
times (3,5–7). Therefore, when medical professionals
assess the effect of aggressive surgical intervention on the
patients’ survival, they should consider the age factor (18).
4.3. Preoperative functional state
Although the scoring system developed by Karnofsky
(19) is frequently used in the literature, researchers
use different scoring systems when assessing patients’
performance levels. This, in turn, produces different
results (7,13). In general, when the preoperative functional
state is studied as an independent variable, patients with
elevated Karnofsky scores have more favorable results
(1,3,4,6–9,13). These studies, however, have an important
limitation: although low preoperative KPS (which is
significantly correlated to high mortality rates) is included
in a statistical assessment, the extent of surgical resection
(which is a crucial prognostic factor in multivariate
analyses) is not (13). Chang et al. (7) reported that both
preoperative KPS and the type of surgery are significantly
correlated with survival time.
This study’s univariate analyses showed that patients’
elevated preoperative KPSs influence survival as an
independent variable, and low KPSs affect survival
adversely. These results are consistent with those of
previous studies (1,3,6–9).
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4.4. Postoperative functional state
There are 2 other clinical variables that determine the
reaction of radiation in cases with GBM: pre-RT KPS and
the degree of surgical resection applied (5). The mechanism
of the correlation between KPS and radiation response
is unknown. In malignant gliomas in patients with low
KPSs, high tumor metabolism can be observed through
18-fluorodeoxyglucose positron emission tomography
(PET scanning) (20).
In the present study, univariate and multivariate
analyses have shown that a high postoperative KPS is
associated with a considerable increase in the rate of
survival, which is consistent with the findings from
previous studies (1,5,13). Wang et al. (21) reported that the
only independent prognostic factors for a longer overall
survival were gross total resection and higher KPS in
multivariate analysis.
4.5. Complications
This study detected that complications developing within
the first postoperative month have an adverse effect on
survival. Patients without complications have higher
survival rates.
Previous studies have not significantly considered the
effects of postoperative complications on MA patients’
survival times, but this issue has gained importance in
today’s studies owing to the complications’ crucial adverse
effects. Almost all previous studies observed patients
during the postoperative weeks and months, without
presenting surgical mortalities and mortality rates. Such
an approach may produce false results concerning the
effects of surgical operations (15).
4.6. Radiotherapy
It has been propounded that younger GBM patient age
correlates with a better reaction to RT. Other important
clinical variables that point to better reactions to radiation
are high postoperative KPSs and extensive surgical resection
(5). Theoretical tumor models indicate that tumors with
smaller diameters can display greater radiosensitivity
(22). In this study, small postoperative tumor volume was
revealed as a prognostic factor. According to this result,
small postoperative tumor volume might increase the
response to the RT and hence improve the prognosis.
Recent studies suggest that differences in the molecular
pathology of GBM tumors might be related to sensitivity
to therapy. Yount et al. (23) found that GBM cells in which
p53 functions are missing undergo less apoptosis after
ionizing radiation therapy. GBM cells interacting with the
p53 function undergo more prolonged cell cycles arrested
by apoptosis (24). However, the p53 mutation is most
common in GBM cases in young patients. That indicates
the presence of a correlation between other molecular
defects and radiation reaction assessed radiographically
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in GBM (25). GBM in older patients tends to display the
deletion of the tenth chromosome, and it is probable that
the genes that are important in terms of radiosensitivity in
gliomas are located on this chromosome (26). Some studies
report that radiation reactions are visually evaluated more
accurately in patients with malign gliomas who have
shown favorable performances and undergone more
comprehensive resections (21). The cause of the correlation
between KPS and radiation reaction is unknown. However,
in some studies, PET has shown that malign gliomas in
patients with low KPSs have higher tumor metabolisms
(20). Tanaka et al. (27) reported that a patient with lower
KPS who underwent resection appeared to benefit from
radiotherapy. When a patient underwent biopsy, he or she
did not benefit from RT. The KPS was improved after RT
in the resection group.
This study found that RT is an independent variable
that is statistically significant in both Kaplan–Meier life
analysis and univariate Cox regression analysis. RT lost
its statistical significance in multivariate Cox regression
analysis, however, when CT was added to the analysis.
These conclusions indicate that RT has prognostic value in
MAs during the postoperative period, and they verify the
literature findings (2,4,6,8,27)
4.7. Chemotherapy
Patients who received CT had longer survival times in
both univariate and multivariate analyses. When RT was
ignored in multivariate Cox regression analysis, CT had
no effect on survival time; this demonstrates the effect
of CT on survival after RT. It was also observed that CT
application following RT was an important independent
variable affecting survival.
Filippini et al. (8) found, in a study of 676 patients, that
CT is statistically significant with respect to survival. In
addition, making references to the literature, the authors
stressed that in patients with recurrent glioblastoma,
second-line CT has statistically significant effects on
survival. Barker et al. (16) reported that when TMZ is
given concomitantly with RT, the survival of elderly
patients with GBM may be improved. Kaur et al. (28)
reported that chemotherapy was not a prognostic factor
in the multivariate analysis, nor was localization of the
tumor. On the other hand, age and extent of resection were
significant prognostic factors in the multivariate analysis.
Iwadate et al. (29) reported great GBM
chemosensitivity in the absence of a mutation in p53, the
tumor-repressing gene. SongTao et al. (30) reported that
the best chemosensitivity was associated with isocitrate
dehydrogenase mutation and O-(6)-methylguanine
DNA methyltransferase promoter methylation, but p53
expression was not.
In conclusion, all independent variables interact with
each other. Even though surgical resection degree is
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not a prognostic factor, according to the univariate and
multivariate analyses, postoperative tumor volume was
revealed as a prognostic factor in the multivariate analysis.
Therefore, surgical resection is an important prognostic

variable, along with age, chemotherapy, postoperative
KPS, and postoperative tumor volume. Extensive surgical
resection is an important variable because small tumor
volume has a significant effect on prognosis.
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